CTOs on the Move

Sentigen Biosciences

www.sentigen.com

 
Sentigen Biosciences is a Phillipsburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sentigen.com
  • 445 Marshall St
    Phillipsburg, NJ USA 08865
  • Phone: 908.387.1673

Executives

Name Title Contact Details

Similar Companies

CE and IC Inc

CE and IC Inc is a Burlington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Essential Group

Essential Group is a Gurnee, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Creative Biogene.Inc

Creative Biogene.Inc is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intarcia

We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.

G1 Therapeutics

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.